Akebia develops and sells kidney disease medicines, including the anemia treatment Vafseo and the phosphorus control drug Auryxia. It last closed at $0.39 on Nov 20, down 8.71% on the day. The next earnings report for AKBA is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, AKBA reported EPS of -$0.05 on revenue of $36.9M, with revenue down 37.2% from a year ago. Over its last 8 reports the stock moved an average of 18.4% the session after earnings. Over the last 12 months AKBA insiders bought $87K of stock on the open market and sold $963K, according to SEC Form 4 filings.
AI Auto Pilots
Is AKBA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AKBA.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on AKBAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
AKBA · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 45% below its 20 day and 86% below its 50 day average. It is 180% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $0.37, and the nearest resistance the Pivot at $0.40.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 17.0%/day
Key levels
$1.7352 week high+343.6%
$1.08200 day average+176.9%
$0.91100 day average+133.3%
$0.7250 day average+84.6%
$0.58Swing high (Nov 11)+48.7%
$0.5620 day average+43.6%
$0.42Pivot R1+7.7%
$0.40Pivot+2.6%
$0.39Last close
$0.37Pivot S1−5.1%
$0.3652 week low−7.7%
$0.36Swing low (Nov 6)−7.7%
Indicators
RSI (14)
32.70
Weak, oversold below 30
Neutral
MACD
-0.09
Below its signal line
Bearish
Stochastic
11.3
Near the bottom of its range
Oversold
ADX (14)
28.9
Trending down
Williams %R
-93.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-90.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−3.9%
Change over 10 sessions
Bearish
ATR (14)
$0.07
Typical daily range, 17.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 46.1%/day
Key levels
$1.7352 week high+343.6%
$1.08200 day average+176.9%
$0.91100 day average+133.3%
$0.7250 day average+84.6%
$0.58Swing high (Nov 11)+48.7%
$0.5620 day average+43.6%
$0.42Pivot R1+7.7%
$0.40Pivot+2.6%
$0.39Last close
$0.37Pivot S1−5.1%
$0.3652 week low−7.7%
$0.36Swing low (Nov 6)−7.7%
Indicators
RSI (14)
30.26
Weak, oversold below 30
Neutral
MACD
-0.22
Below its signal line
Bearish
Stochastic
8.0
Near the bottom of its range
Oversold
ADX (14)
27.4
Trending down
Williams %R
-96.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-156.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−59.5%
Change over 10 sessions
Bearish
ATR (14)
$0.18
Typical daily range, 46.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AKBA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how AKBA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow AKBA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for AKBAHow many large options trades hit AKBA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in AKBA in the last 90 days.
From SEC Form 4 filings by AKBA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AKBA is in one of them and how their past AKBA trades turned out.
Akebia is a biopharmaceutical company based in Waltham, Massachusetts, that develops and sells medicines for people with kidney disease. Its main product, Vafseo, is an oral treatment for anemia caused by chronic kidney disease in adults on dialysis. Its second product, Auryxia, is an oral medicine used to control phosphorus levels in dialysis patients and to treat iron deficiency anemia in adults with kidney disease who are not on dialysis. The company also develops treatments for rare kidney conditions.